{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T13:00:20Z","timestamp":1771851620861,"version":"3.50.1"},"reference-count":67,"publisher":"Japan Society for Clinical Immunology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn.J.clin.Immun","Jpn. J. Clin. Immunol."],"published-print":{"date-parts":[[2017]]},"DOI":"10.2177\/jsci.40.102","type":"journal-article","created":{"date-parts":[[2017,6,11]],"date-time":"2017-06-11T18:15:06Z","timestamp":1497204906000},"page":"102-108","source":"Crossref","is-referenced-by-count":10,"title":["Immune-related adverse events of immune checkpoint inhibitors"],"prefix":"10.2177","volume":"40","author":[{"given":"Hiroki","family":"TADANO","sequence":"first","affiliation":[{"name":"Department of Pathology, Sapporo Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"TORIGOE","sequence":"additional","affiliation":[{"name":"Department of Pathology, Sapporo Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"972","reference":[{"key":"1","unstructured":"1) Pardoll, D.M.: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer.<\/i> 12<\/b>: 252-264, 2012."},{"key":"2","unstructured":"2) Chen, T.W., et al.: A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann Oncol<\/i>. 26<\/b>: 1824-1829, 2015."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Fukushima, S.: A review of adverse events caused by immune checkpoint inhibitors. Nihon Rinsho Meneki Gakkai Kaishi.<\/i> 39<\/b>: 30-36, 2016.","DOI":"10.2177\/jsci.39.30"},{"key":"4","unstructured":"4) Rudd, C.E., et al.: CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev<\/i>. 229<\/b>: 12-26, 2009."},{"key":"5","unstructured":"5) Tivol, E.A., et al.: Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity<\/i>. 3<\/b>: 541-547, 1995."},{"key":"6","unstructured":"6) Waterhouse, P., et al.: Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science<\/i>. 270<\/b>: 985-988, 1995."},{"key":"7","unstructured":"7) Keir, M.E., et al.: Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med<\/i>. 203<\/b>: 883-895, 2006."},{"key":"8","unstructured":"8) Okazaki, T., Wang, J.: PD-1\/PD-L pathway and autoimmunity. Autoimmunity<\/i>. 38<\/b>: 353-357, 2005."},{"key":"9","unstructured":"9) Nishimura, H., et al.: Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity<\/i>. 11<\/b>: 141-151, 1999."},{"key":"10","unstructured":"10) Nishimura, H., et al.: Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science<\/i>. 291<\/b>: 319-322, 2001."},{"key":"11","unstructured":"11) Wang, J., et al.: Establishment of NOD-Pdcd1\u2212\/\u2212 mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci U S A<\/i>. 102<\/b>: 11823-11828, 2005."},{"key":"12","unstructured":"12) Boutros, C., et al.: Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol<\/i>. 13<\/b>: 473-486, 2016."},{"key":"13","unstructured":"13) Champiat, S., et al.: Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol<\/i>. 27<\/b>: 559-574, 2016."},{"key":"14","unstructured":"14) Costa, R., et al.: Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. Oncotarget<\/i>. 8<\/b>: 8910-8920, 2017."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) De Velasco, G., et al.: Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1\/PD-L1 Inhibitors in Cancer Patients. Cancer Immunol Res<\/i>, 2017.","DOI":"10.1158\/2326-6066.CIR-16-0237"},{"key":"16","unstructured":"16) Iwama, S., et al.: Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med<\/i>. 6<\/b>: 230ra245, 2014."},{"key":"17","unstructured":"17) Okano, Y., et al.: Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma. Endocr J<\/i>. 63<\/b>: 905-912, 2016."},{"key":"18","unstructured":"18) Caturegli, P., et al.: Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series. Am J Pathol<\/i>. 186<\/b>: 3225-3235, 2016."},{"key":"19","unstructured":"19) Mazanet, M.M., Hughes, C.C.: B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol<\/i>. 169<\/b>: 3581-3588, 2002."},{"key":"20","unstructured":"20) Nakazawa, A., et al.: The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells. Gastroenterology<\/i>. 126<\/b>: 1347-1357, 2004."},{"key":"21","unstructured":"21) Ding, H., et al.: PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis. Clin Immunol<\/i>. 115<\/b>: 184-191, 2005."},{"key":"22","unstructured":"22) Johnson, D.B., et al.: Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma. J Clin Oncol<\/i>. 33<\/b>: e122-124, 2015."},{"key":"23","unstructured":"23) Shirai, T., et al.: Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol<\/i>. 46<\/b>: 86-88, 2016."},{"key":"24","unstructured":"24) Cousin, S., Italiano, A.: Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities. Clin Cancer Res<\/i>. 22<\/b>: 4550-4555, 2016."},{"key":"25","unstructured":"25) Menzies, A.M., et al.: Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol<\/i>, 2016."},{"key":"26","unstructured":"26) Michot, J.M., et al.: Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer<\/i>. 54<\/b>: 139-148, 2016."},{"key":"27","unstructured":"27) Oh, D.Y., et al.: Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire. Cancer Res<\/i>. 77<\/b>: 1322-1330, 2017."},{"key":"28","unstructured":"28) Gibney, G.T., et al.: Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol<\/i>. 17<\/b>: e542-e551, 2016."},{"key":"29","unstructured":"29) Martens, A., et al.: Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. Clin Cancer Res<\/i>. 22<\/b>: 2908-2918, 2016."},{"key":"30","unstructured":"30) Topalian, S.L., et al.: Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer.<\/i> 16<\/b>: 275-287, 2016."},{"key":"31","unstructured":"31) Manson, G., et al.: Biomarkers associated with checkpoint inhibitors. Ann Oncol<\/i>. 27<\/b>: 1199-1206, 2016."},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Bergqvist, V., et al.: Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother<\/i>, 2017.","DOI":"10.1007\/s00262-017-1962-6"},{"key":"33","unstructured":"33) Chia, P.L., John, T.: Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Non-Small Cell Lung Cancer (NSCLC). J Immunother<\/i>. 39<\/b>: 202-204, 2016."},{"key":"34","unstructured":"34) Collins, L.K., et al.: Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer<\/i>, 2016."},{"key":"35","unstructured":"35) Damsky, W., et al.: Development of bullous pemphigoid during nivolumab therapy. JAAD Case Rep<\/i>. 2<\/b>: 442-444, 2016."},{"key":"36","unstructured":"36) Koelzer, V.H., et al.: Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy. J Immunother Cancer<\/i>. 4<\/b>: 47, 2016."},{"key":"37","unstructured":"37) Naidoo, J., et al.: Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. Cancer Immunol Res<\/i>. 4<\/b>: 383-389, 2016."},{"key":"38","unstructured":"38) Uemura, M., et al.: A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1. J Immunother Cancer<\/i>. 4<\/b>: 55, 2016."},{"key":"39","unstructured":"39) Gonzalez-Rodriguez, E., Rodriguez-Abreu, D.: Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events. Oncologist<\/i>. 21<\/b>: 804-816, 2016."},{"key":"40","unstructured":"40) Miyoshi, Y., et al.: Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes. Tohoku J Exp Med<\/i>. 239<\/b>: 155-158, 2016."},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Osorio, J.C., et al.: Antibody-Mediated Thyroid Dysfunction During T-cell Checkpoint Blockade in Patients with Non-Small Cell Lung Cancer. Ann Oncol<\/i>, 2016.","DOI":"10.1093\/annonc\/mdw640"},{"key":"42","unstructured":"42) Hickmott, L., et al.: Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature. Target Oncol<\/i>. 12<\/b>: 235-241, 2017."},{"key":"43","unstructured":"43) Munakata, W., et al.: Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma. Int J Hematol<\/i>. 105<\/b>: 383-386, 2017."},{"key":"44","unstructured":"44) Heinzerling, L., et al.: Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer<\/i>. 4<\/b>: 50, 2016."},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Tadokoro, T., et al.: Acute Lymphocytic Myocarditis With Anti-PD-1 Antibody Nivolumab. Circ Heart Fail<\/i>. 9, 2016.","DOI":"10.1161\/CIRCHEARTFAILURE.116.003514"},{"key":"46","unstructured":"46) Wang, D.Y., et al.: Cardiovascular Toxicities Associated with Cancer Immunotherapies. Curr Cardiol Rep<\/i>. 19<\/b>: 21, 2017."},{"key":"47","unstructured":"47) Lankes, K., et al.: Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis. Oncoimmunology<\/i>. 5<\/b>: e1128611, 2016."},{"key":"48","unstructured":"48) Carbonnel, F., et al.: Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora? Semin Immunopathol<\/i>. 39<\/b>: 327-331, 2017."},{"key":"49","unstructured":"49) Ikeuchi, K., et al.: Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report. Lung Cancer<\/i>. 99<\/b>: 148-150, 2016."},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Wang, W., et al.: Risk of hepatotoxicity in cancer patients Treated with immune checkpoint inhibitors: a systematic review and meta-analysis of published data. Int J Cancer<\/i>, 2017.","DOI":"10.1002\/ijc.30678"},{"key":"51","unstructured":"51) Sano, T., et al.: Nivolumab-induced organizing pneumonia in a melanoma patient. Jpn J Clin Oncol<\/i>. 46<\/b>: 270-272, 2016."},{"key":"52","unstructured":"52) Maurice, C., et al.: Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma. Cancer Immunol Res<\/i>. 3<\/b>: 1299-1302, 2015."},{"key":"53","unstructured":"53) Abe, J., et al.: Nivolumab-Induced Severe Akathisia in an Advanced Lung Cancer Patient. Am J Case Rep<\/i>. 17<\/b>: 880-882, 2016."},{"key":"54","unstructured":"54) Khoja, L., et al.: Eosinophilic Fasciitis and Acute Encephalopathy Toxicity from Pembrolizumab Treatment of a Patient with Metastatic Melanoma. Cancer Immunol Res<\/i>. 4<\/b>: 175-178, 2016."},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Cappelli, L.C., et al.: Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: A systematic review of the literature. Arthritis Care Res<\/i> (Hoboken<\/i>), 2016.","DOI":"10.1002\/acr.23177"},{"key":"56","unstructured":"56) Cappelli, L.C., et al.: Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities. RMD Open<\/i>. 2<\/b>: e000321, 2016."},{"key":"57","unstructured":"57) Cappelli, L.C., et al.: Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis<\/i>. 76<\/b>: 43-50, 2017."},{"key":"58","unstructured":"58) Antoun, J., et al.: Ocular and orbital side-effects of checkpoint inhibitors: a review article. Curr Opin Oncol<\/i>. 28<\/b>: 288-294, 2016."},{"key":"59","unstructured":"59) Hanna, K.S.: A Rare Case of Pembrolizumab-Induced Uveitis in a Patient with Metastatic Melanoma. Pharmacotherapy<\/i>. 36<\/b>: e183-e188, 2016."},{"key":"60","unstructured":"60) Zibelman, M., et al.: Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab. J Immunother Cancer<\/i>. 4<\/b>: 8, 2016."},{"key":"61","unstructured":"61) Murakami N, et al.: Renal complications of immune checkpoint blockade. Curr Probl Cancer<\/i>, 2016."},{"key":"62","unstructured":"62) Vandiver, J.W., et al.: Severe Hyponatremia and Immune Nephritis Following an Initial Infusion of Nivolumab. Target Oncol<\/i>. 11<\/b>: 553-556, 2016."},{"key":"63","unstructured":"63) Wanchoo, R., et al.: Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review. Am J Nephrol<\/i>. 45<\/b>: 160-169, 2017."},{"key":"64","unstructured":"64) Shiuan, E., et al.: Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. J Immunother Cancer<\/i>. 5<\/b>: 8, 2017."},{"key":"65","unstructured":"65) Koelzer, V.H., et al.: Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study. J Immunother Cancer<\/i>. 4<\/b>: 13, 2016."},{"key":"66","doi-asserted-by":"crossref","unstructured":"66) Montaudie, H., et al.: Pulmonary sarcoid-like granulomatosis induced by nivolumab. Br J Dermatol<\/i>, 2016.","DOI":"10.1111\/bjd.14808"},{"key":"67","unstructured":"67) Suozzi, K.C., et al.: Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy. JAAD Case Rep<\/i>. 2<\/b>: 264-268, 2016."}],"container-title":["Japanese Journal of Clinical Immunology"],"original-title":["\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u5264\u306e\u514d\u75ab\u6027\u526f\u4f5c\u7528"],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsci\/40\/2\/40_102\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T18:17:58Z","timestamp":1569435478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsci\/40\/2\/40_102\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2177\/jsci.40.102","relation":{},"ISSN":["0911-4300","1349-7413"],"issn-type":[{"value":"0911-4300","type":"print"},{"value":"1349-7413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}